The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …

The COVID-19 pandemic has plagued the world for over three years since discovering the
causative virus, SARS-CoV-2, in China. The rampant spread of the virus led to the loss of …

Objective: We aim to describe the safety and efficacy of sotrovimab in severe cases of
COVID-19 in immunocompromised hosts. Methods: We used a retrospective multicenter …

Aims This study aimed to evaluate the efficacy and safety of regdanvimab, an anti‐SARS‐
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …

Methods: A descriptive analysis of hospitalization and treatment of COVID-19 patients with
drugs centrally procured by the BMG at St. Georg Hospital, Leipzig, Germany, for the period …

We present the case of a 76-year-old male patient persistently infected by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in the setting of a stage IIIC cutaneous …

Background & Aims: Regdanumab is a monoclonal antibody that is widely used to treat the
patients with COVID-19. The aim of this study was to investigate the clinical effectiveness of …

Background Despite widespread implementation of vaccination against coronavirus disease
2019 (COVID-19), solid organ transplant recipients (SOTRs) can remain particularly …

La COVID-19 ha demostrado ser especialmente agresiva con los pacientes con
enfermedad renal crónica (ERC). La menor tasa de respuesta inmunológica y la mayor …

Khorramnia S, Jalili M, Salajegheh M, Mansouri M. EFFICACY OF BAMLANIVIMAB
COMPARED TO STANDARD CARE IN TREATMENT OF THE PATIENTS WITH COVID-19: A …